Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine

ConclusionsThe identifiedCES1 polymorphisms might provide guide for the identification of gastroenteric cancer patients who were likely to benefit from capecitabine-based chemotherapy.

Source: Cancer Chemotherapy and Pharmacology - February 14, 2021 Category: Cancer & Oncology Source Type: research